These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 20660692)

  • 1. In vitro pharmacokinetic and pharmacodynamic evaluation of S-013420 against Haemophilus influenzae and Streptococcus pneumoniae.
    Homma T; Hori T; Ohshiro M; Maki H; Yamano Y; Shimada J; Kuwahara S
    Antimicrob Agents Chemother; 2010 Oct; 54(10):4300-5. PubMed ID: 20660692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibacterial activity and PK/PD of ceftriaxone against penicillin-resistant Streptococcus pneumoniae and beta-lactamase-negative ampicillin-resistant Haemophilus influenzae isolates from patients with community-acquired pneumonia.
    Ohno A; Ishii Y; Kobayashi I; Yamaguchi K
    J Infect Chemother; 2007 Oct; 13(5):296-301. PubMed ID: 17982717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics/Pharmacodynamics of Peptide Deformylase Inhibitor GSK1322322 against Streptococcus pneumoniae, Haemophilus influenzae, and Staphylococcus aureus in Rodent Models of Infection.
    Hoover J; Lewandowski T; Straub RJ; Novick SJ; DeMarsh P; Aubart K; Rittenhouse S; Zalacain M
    Antimicrob Agents Chemother; 2016 Jan; 60(1):180-9. PubMed ID: 26482300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of pharmacokinetic/pharmacodynamic relationships of PD-0162819, a biotin carboxylase inhibitor representing a new class of antibacterial compounds, using in vitro infection models.
    Ogden A; Kuhn M; Dority M; Buist S; Mehrens S; Zhu T; Xiao D; Miller JR; Hanna D
    Antimicrob Agents Chemother; 2012 Jan; 56(1):124-9. PubMed ID: 21986824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How can we predict bacterial eradication?
    Jacobs MR
    Int J Infect Dis; 2003 Mar; 7 Suppl 1():S13-20. PubMed ID: 12839703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic-Pharmacodynamic Target Attainment Analyses Evaluating Omadacycline Dosing Regimens for the Treatment of Patients with Community-Acquired Bacterial Pneumonia Arising from Streptococcus pneumoniae and Haemophilus influenzae.
    Bhavnani SM; Hammel JP; Lakota EA; Trang M; Bader JC; Bulik CC; VanScoy BD; Rubino CM; Huband MD; Friedrich L; Steenbergen JN; Ambrose PG
    Antimicrob Agents Chemother; 2023 Apr; 67(4):e0221321. PubMed ID: 36946741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic/pharmacodynamic modeling for concentration-dependent bactericidal activity of a bicyclolide, modithromycin.
    Katsube T; Wajima T; Yamano Y; Yano Y
    J Pharm Sci; 2014 Apr; 103(4):1288-97. PubMed ID: 24523230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic/Pharmacodynamic Evaluation of a Novel Aminomethylcycline Antibiotic, KBP-7072, in the Neutropenic Murine Pneumonia Model against Staphylococcus aureus and Streptococcus pneumoniae.
    Lepak AJ; Zhao M; Liu Q; Wang P; Wang Y; Bader JC; Ambrose PG; Andes DR
    Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30559140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamics of cefprozil against Haemophilus influenzae in an in vitro pharmacodynamic model.
    Smith PF; Tsuji B; Booker BM; Forrest A; Bajic S; Kelchlin P; Bhavnani SM; Jones RN; Ambrose PG
    Diagn Microbiol Infect Dis; 2006 Dec; 56(4):379-86. PubMed ID: 16930921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of nine oral agents against gram-positive and gram-negative bacteria encountered in community-acquired infections: use of pharmacokinetic/pharmacodynamic breakpoints in the comparative assessment of beta-lactam and macrolide antimicrobial agents.
    Peric M; Browne FA; Jacobs MR; Appelbaum PC
    Clin Ther; 2003 Jan; 25(1):169-77. PubMed ID: 12637118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamic activity of telithromycin at simulated clinically achievable free-drug concentrations in serum and epithelial lining fluid against efflux (mefE)-producing macrolide-resistant Streptococcus pneumoniae for which telithromycin MICs vary.
    Zhanel GG; Johanson C; Laing N; Hisanaga T; Wierzbowski A; Hoban DJ
    Antimicrob Agents Chemother; 2005 May; 49(5):1943-8. PubMed ID: 15855517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic-Pharmacodynamic Evaluation of Gepotidacin against Gram-Positive Organisms Using Data from Murine Infection Models.
    Bulik CC; Okusanya ÓO; Lakota EA; Forrest A; Bhavnani SM; Hoover JL; Andes DR; Ambrose PG
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27872075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative in vitro activity of telithromycin against macrolide-resistant and -susceptible Streptococcus pneumoniae, Moraxella catarrhalis and Haemophilus influenzae.
    Walsh F; Carnegy F; Willcock J; Amyes S
    J Antimicrob Chemother; 2004 May; 53(5):793-6. PubMed ID: 15056640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters.
    Jacobs MR
    Clin Microbiol Infect; 2001 Nov; 7(11):589-96. PubMed ID: 11737083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro and in vivo pharmacokinetic/pharmacodynamic activity of clofoctol.
    Scaglione F; Dugnani S; Lucini V; Pannacci M; Paraboni L
    J Chemother; 2012 Aug; 24(4):201-6. PubMed ID: 23040683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of Solithromycin (CEM-101) for Experimental Otitis Media Caused by Nontypeable Haemophilus influenzae and Streptococcus pneumoniae.
    Figueira M; Fernandes P; Pelton SI
    Antimicrob Agents Chemother; 2016 Sep; 60(9):5533-8. PubMed ID: 27401563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo pharmacodynamics of a new oxazolidinone (linezolid).
    Andes D; van Ogtrop ML; Peng J; Craig WA
    Antimicrob Agents Chemother; 2002 Nov; 46(11):3484-9. PubMed ID: 12384354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AWARE Ceftaroline Surveillance Program (2008-2010): trends in resistance patterns among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States.
    Pfaller MA; Farrell DJ; Sader HS; Jones RN
    Clin Infect Dis; 2012 Sep; 55 Suppl 3():S187-93. PubMed ID: 22903951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamic activity of telithromycin against macrolide-susceptible and macrolide-resistant Streptococcus pneumoniae simulating clinically achievable free serum and epithelial lining fluid concentrations.
    Zhanel GG; Johanson C; Hisanaga T; Mendoza C; Laing N; Noreddin A; Wierzbowski A; Hoban DJ
    J Antimicrob Chemother; 2004 Dec; 54(6):1072-7. PubMed ID: 15531596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamic analysis of the microbiological efficacy of telithromycin in patients with community-acquired pneumonia.
    Shi J; Pfister M; Jenkins SG; Chapel S; Barrett JS; Port RE; Howard D
    Clin Pharmacokinet; 2005; 44(3):317-29. PubMed ID: 15762772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.